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Abstract
A right heart catheterization with reversibility testing is recommended for the diagnosis and
treatment of pulmonary arterial hypertension. In this 24 years-old woman, the inhalation of 5 μg
iloprost transiently decreased mean pulmonary artery pressure from 62 to 36 mmHg and
pulmonary vascular resistance from 11.0 to 4.9 Wood units, meeting the criteria of a "positive
response". The echocardiographic examination showed normalization of right heart chamber
dimensions and of the right ventricular performance (Tei) index. Pulsed tissue Doppler imaging of
the right ventricle showed a decrease in the isovolumic relaxation time from 102 to 73 ms, and an
increase of the E/A ratio from 0.72 to 1.38, together with marked improvements in mid-apical free
wall systolic strain and strain rate. A positive response to reversibility testing of pulmonary arterial
hypertension may be associated with quasi normalization of right ventricular function, in spite of
still elevated pulmonary artery pressure.
Introduction
The diagnosis of pulmonary arterial hypertension (PAH)
relies on a right heart catheterization, with reversibility
testing to identify patients who might benefit from cal-
cium channel blocker therapy [1]. A positive response is
defined by a decrease in mean pulmonary artery pressure
(Ppa) by at least 10 mmHg to below 40 mmHg, with
unchanged or increased cardiac output (Q), with the inha-
lation of nitric oxide (NO) or infusion of epoprostenol or
adenosine [1]. Treatment of these "responders" with cal-
cium channel blockers may result in sustained clinical
benefit [2]. A logical explanation for these beneficial clin-
ical effects is an improved right ventricular function (RV)
because of a decreased afterload. However, little is known
about the effects of reversibility testing on RV function.
We therefore report the evaluated RV function with Dop-
pler echocardiography and pulse tissue Doppler imaging
in a case of a patients with idiopathic PAH who presented
with a borderline response to inhaled NO and a more
definitive response to the inhaled prostacyclin analogue
iloprost.
Case presentation
This 24 years-old woman with idiopathic PAH had been
referred for right heart catheterization and reversibility
testing. The results are shown in Table 1. The "responder"
criteria were almost met with the inhalation of 20 ppm of
NO, and definitively with the inhalation of 5 μg of ilo-
prost, which furthermore decreased PVR by more than
50%.
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An echocardiography examination with tissue Doppler
imaging (TDI) was performed as previously reported [3].
Mean Ppa was estimated from the acceleration time of
pulmonary flow, measured at the RV outflow tract [4].
Right ventricular function was assessed by measurements
of the area shortening fraction, the RV to left ventricular
(LV) end-diastolic area ratio (4 chamber apical view) and
the LV eccentricity index (parasternal short axis view) [5].
A index of global RV function was measured as reported
by Tei et al (the "Tei index") [6]. Pulsed TDI was applied
to measure mitral and tricuspid annuli peak velocities
during systole (S), early diastole (E) and late diastole (A)
[7]. The isolvolumic relaxation time (IVRT) was measured
as the time between the end of the S and beginning of the
E waves. Strain and strain rate measurements were
obtained in 2 operator selected regions of interest, the
mid-basal and the mid-apical segments of the free RV wall
[3]. All the measurements were obtained before and dur-
ing the reversibility tests.
The acceleration time of pulmonary blood flow changed
from 80 ms to 81 ms (NO) and 103 ms (iloprost), indi-
cating a decrease in Ppa that was more important with ilo-
prost than with NO. The four chamber apical view
showed that the RV came back to a near-normal shape,
with a RV/LV end-diastolic area ratio decreased from 91 to
54% with iloprost (Figure 1). The short axis view showed
a return of the LV to a normal rounded shape, with an
eccentricity index in end-diastole: from 1.8 to 1.1 (NO)
and to 1 (iloprost) and in end-systole from 2.3 to 1.2
(NO) and to 1.1 (iloprost) (Figure 2). The RV area short-
ening fraction increased from 11 to 43% with iloprost,
and the RV Tei index was normalized, from 0.31 to 0.14
(NO) and to 0.16 (iloprost). Pulsed TDI recorded at the
tricuspid annulus showed a marked increase in S waves,
from 11 to 12 and 13.5 cm/sec, and in E waves, from 8 to
9.5 and to 11 cm/sec and a decrease in A wave (from 11 to
8.5 and to 8 cm/sec) with inversion of the E/A ratio (from
0.72 to 1.12 to 1.38), and a decrease in IVRT (from 102 to
75 and to 73 msec), whereas these effects were not
observed at the mitral annulus (Figure 3). Along the RV
free wall, systolic strain increased at the mid-apex, from
19 to 41 and to 37%, but not at the mid-base, from 23 to
23 and to 22%. The changes in systolic strain rate were
similar, with at mid-apex from 1.1 to 3.2 and to 3.6/sec
and at mid-base from 1.1 to 1.1 and 1.1/sec (Figures 4 and
5).
Table 1: Hemodynamic measurements at baseline and during 
the inhalation of 20 ppm nitric oxide (NO) and 5 μg of iloprost.
Variables Baseline Inhaled NO Iloprost
Ppa, mmHg 62 45 36
Ppao, mmHg 9 11 10
Pra, mmHg 7 6 7
Q, L/min 4.8 4.5 5.3
PVR, WU 11.0 7.6 4.9
Abbreviations: Ppa = mean pulmonary artery pressure. Ppao = 
pulmonary occluded pulmonary artery pressure. Pra = right atrial 
pressure. Q = cardiac output. PVR = pulmonary vascular resistance.
Four chamber apical view before (left) and during iloprost  inhalation (right) Figure 1
Four chamber apical view before (left) and during ilo-
prost inhalation (right).
Parasternal short axis view before (left), during nitric oxide  (NO) inhalation (middle) and during iloprost inhalation  (right) Figure 2
Parasternal short axis view before (left), during nitric 
oxide (NO) inhalation (middle) and during iloprost 
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Because the criteria of reversibility were met [2], the
patient was initially treated with calcium channel block-
ers. This treatment was poorly tolerated, and soon
replaced by the endothelin receptor antagonists sitaxsen-
tan, which resulted in a stabilization in New York Heart
Association functional class II and an acceptable quality
of life.
Discussion
The present results show that all echocardiographic indi-
ces of both systolic and diastolic RV and LV function
returned to normal or near-normal during a positive
reversibility test, in spite of the fact that Ppa remained
higher than normal.
The symptomatology and prognosis of PAH are largely
determined by RV function adaptation. Accordingly, right
atrial pressure and cardiac output have been shown to be
better predictors of outcome than the actual level of Ppa
[8]. Recent studies have drawn attention to the impor-
tance of RV systolic function adaptation [9]. End-systolic
elastance as a measure of contractility has been shown to
be increased in idiopathic PAH, though not enough to
match increased afterload as measured by arterial
elastance [10]. Accordingly, the RV is chronically uncou-
pled in PAH, accounting for inability to increase flow out-
put in response to peripheral demand by the exercising
muscles. However, chronically increased systolic function
may allow for an only partially unloaded RV to normalize
its coupling to the pulmonary circulation, explaining the
marked improvement of indices of RV function in the
Pulmonary artery pressure (top) and pulsed-tissue Doppler traces at the tricuspid annulus (middle) and at the mitral annulus  (at the bottom) before and during the inhalation of iloprost Figure 3
Pulmonary artery pressure (top) and pulsed-tissue Doppler traces at the tricuspid annulus (middle) and at the 
mitral annulus (at the bottom) before and during the inhalation of iloprost. The white arrows show the pulmonary 
valve closure.Cardiovascular Ultrasound 2009, 7:9 http://www.cardiovascularultrasound.com/content/7/1/9
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present case. In addition, our results are in keeping with
the notion that abnormal RV and LV diastolic changes in
PAH are secondary to systolic RV failure.
It is if interest that TDI indices of systolic function changes
were essentially mid-apical, confirming a previous report
in a PAH patient with abrupt decrease in PVR after a dou-
ble lung transplantation [11]. While still unexplained, this
observation underscores the need of regional function
measurements, which are possible with TDI, for the com-
plete description of RV function changes.
The decrease in Ppa and PVR in the present PAH patient
was more important with inhaled iloprost than with
inhaled NO, so that the "responder" criteria were actually
only met with inhaled iloprost. Inhaled iloprost is not rec-
ommended for reversibility testing [1], but it has been
reported previously to be a more potent pulmonary
vasodilator intervention than inhaled NO in PAH patients
[12].
Conclusion
Decreased Ppa and PVR during reversibility testing in PAH
may be associated with a quasi-normalization of RV func-
tion, accounting for clinical improvement even if pulmo-
nary hemodynamics are not completely reversed back to
normal.
Consent
Written informed consent was obtained from the patient
of this case report. A copy of the written informed consent
Systolic strain recorded along the right ventricular free wall, at the mid-base (yellow trace) and at the mid-apex (green trace),  before and during reversibility testing Figure 4
Systolic strain recorded along the right ventricular free wall, at the mid-base (yellow trace) and at the mid-
apex (green trace), before and during reversibility testing. AVO indicates the pulmonary valve opening and AVC the 
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